Therapeutic implications of B-RAF mutations in colorectal cancer.

Abstract excerpt

Colorectal cancers (CRC) with B-RAF mutation carry a particularly poor prognosis. In this context, the value of first-line intensified chemotherapy associated with an anti-VEGF (Vascular endothelial growth factor) to treat metastatic CRC has recently been called into question. In patients with mutated B-RAF, the efficacy of first-line anti-EGFR (Epidermal Growth Factor Receptor) associated with chemotherapy for...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Neoplasms
• Share to Mutation
• Share to Prognosis